Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.
T cells
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
donor lymphocyte infusion (DLI)
exhaustion markers
graft-versus-leukemia
immunotherapy
spectral flow cytometry
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
07
2022
accepted:
20
09
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
26
10
2022
Statut:
epublish
Résumé
Identification of immune phenotypes linked to durable graft-versus-leukemia (GVL) response following donor lymphocyte infusions (DLI) is of high clinical relevance. In this prospective observational study of 13 AML relapse patients receiving therapeutic DLI, we longitudinally investigated changes in differentiation stages and exhaustion markers of T cell subsets using cluster analysis of 30-color spectral flow cytometry during 24 months follow-up. DLI cell products and patient samples after DLI were analyzed and correlated to the clinical outcome. Analysis of DLI cell products revealed heterogeneity in the proportions of naïve and antigen experienced T cells. Cell products containing lower levels of effector memory (eff/m) cells and higher amounts of naïve CD4
Identifiants
pubmed: 36275657
doi: 10.3389/fimmu.2022.999163
pmc: PMC9579313
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
999163Informations de copyright
Copyright © 2022 Odak, Sikora, Riemann, Bayir, Beck, Drenker, Xiao, Schneider, Dammann, Stadler, Eder, Ganser, Förster, Koenecke and Schultze-Florey.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2012 Apr 5;119(14):3256-62
pubmed: 22337715
Cell Rep. 2021 Nov 9;37(6):109992
pubmed: 34758319
Nat Med. 2019 Apr;25(4):603-611
pubmed: 30911134
Br J Haematol. 2019 Jul;186(1):60-71
pubmed: 30916396
Bone Marrow Transplant. 2022 Feb;57(2):215-223
pubmed: 34750562
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2014 Feb 27;123(9):1412-21
pubmed: 24357730
Clin Cancer Res. 2002 Jul;8(7):2052-60
pubmed: 12114403
Bone Marrow Transplant. 2021 Jan;56(1):137-143
pubmed: 32624583
JAMA Oncol. 2018 Sep 1;4(9):1245-1253
pubmed: 30003233
Nat Commun. 2020 Aug 24;11(1):4227
pubmed: 32839441
Clin Diagn Lab Immunol. 2000 May;7(3):352-9
pubmed: 10799445
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
J Clin Oncol. 2021 Feb 10;39(5):397-418
pubmed: 33434060
J Clin Oncol. 1997 Feb;15(2):433-44
pubmed: 9053463
N Engl J Med. 2009 Jul 30;361(5):478-88
pubmed: 19641204
Immunol Cell Biol. 2021 Aug;99(7):680-696
pubmed: 33797774
Br J Haematol. 2014 Aug;166(3):452-5
pubmed: 24661112
Blood. 1996 Mar 15;87(6):2195-204
pubmed: 8630379
Bone Marrow Transplant. 2019 Oct;54(10):1662-1667
pubmed: 30833743
Clin Cancer Res. 2010 May 15;16(10):2729-39
pubmed: 20460482
Leukemia. 2018 Feb;32(2):492-498
pubmed: 28642591
Leukemia. 2004 Aug;18(8):1430-3
pubmed: 15201854
Cancer Discov. 2022 Jun 2;12(6):1449-1461
pubmed: 35255120
Front Immunol. 2019 Jul 09;10:1542
pubmed: 31354710
Cytometry A. 2022 Apr;101(4):325-338
pubmed: 34549881
Cytometry A. 2020 Aug;97(8):824-831
pubmed: 32293794
Clin Transplant. 2014 Aug;28(8):926-34
pubmed: 24931494
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Bone Marrow Transplant. 2016 May;51(5):663-7
pubmed: 26437060
J Clin Invest. 2022 Jun 1;132(11):
pubmed: 35349491
Blood. 2022 May 05;:
pubmed: 35512203
Cytometry A. 2020 Oct;97(10):1044-1051
pubmed: 32830910
Exp Hematol. 2017 Apr;48:1-11
pubmed: 28027963
Biol Blood Marrow Transplant. 2010 May;16(5):565-86
pubmed: 20152921
Nat Immunol. 2017 Apr;18(4):393-401
pubmed: 28218745
Haematologica. 2016 Oct;101(10):1251-1259
pubmed: 27354021
Biol Blood Marrow Transplant. 2019 Jul;25(7):1281-1292
pubmed: 30878607
Blood. 2006 Feb 15;107(4):1325-31
pubmed: 16269610
Blood. 2008 Dec 1;112(12):4371-83
pubmed: 19029455
Biol Blood Marrow Transplant. 2018 Jul;24(7):1350-1359
pubmed: 29649617
Front Immunol. 2022 Mar 14;13:863039
pubmed: 35359969
J Clin Oncol. 2007 Nov 1;25(31):4938-45
pubmed: 17909197
Blood. 1999 Aug 15;94(4):1201-8
pubmed: 10438707
Blood. 1995 Aug 15;86(4):1261-8
pubmed: 7632930
Sci Transl Med. 2013 Feb 27;5(174):174ra27
pubmed: 23447018
Biol Blood Marrow Transplant. 2017 Dec;23(12):2070-2078
pubmed: 28712935
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Blood. 2020 Jun 11;135(24):2182-2191
pubmed: 32478814
J Immunol. 2009 May 15;182(10):5938-48
pubmed: 19414745
Biol Blood Marrow Transplant. 2011 Mar;17(3):374-83
pubmed: 20637880
J Clin Oncol. 2002 Jan 15;20(2):405-12
pubmed: 11786567
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Leukemia. 2021 Oct;35(10):3021-3025
pubmed: 34290358
J Immunol Methods. 2009 Aug 15;347(1-2):87-90
pubmed: 19538964
Front Immunol. 2017 Jun 07;8:496
pubmed: 28638379
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Immunobiology. 2014 Apr;219(4):247-60
pubmed: 24315637
Leukemia. 2007 May;21(5):943-8
pubmed: 17361226
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Blood Adv. 2021 Nov 9;5(21):4485-4499
pubmed: 34535011
Transplant Cell Ther. 2021 Jan;27(1):53.e1-53.e8
pubmed: 32987150